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Pancreatic Tumors in Multiple Endocrine
Neoplasia Type 1
I n this issue, two excellent publications address themanagement of pancreatic neuroendocrine tumors in
patients with Multiple Endocrine Neoplasia Type 1. The
multifocal nature of the disease, the morbidity of removing
the organ at risk, the morbidity of living without a pancreas,
and the inconsistent malignant behavior of the tumors
each affect the individual management decisions during
the lifetime of a patient with MEN-1. The data in these
manuscripts should help to guide us in these decisions.
Dr. Triponez and colleagues from the French Endocrine
Tumor Study Group (GTE) present a summary of patients
from their registry.1 They have chosen 65 patients who
had nonfunctional pancreatic endocrine tumors <2 cm in
size by imaging studies. Their data show that the fre-
quency of tumors increased between 1956 and 2003,
consistent with the increasing sensitivity of imaging
examinations. Fifteen of their 65 patients were managed
by operation. In their registry, three patients are known to
have died of tumor during follow-up. There was no dif-
ference in life expectancy of those patients with non-
functioning pancreatic tumors compared to MEN-1
patients in their registry who did not have imageable
pancreatic tumors.
These data give us an important note of caution
regarding aggressive intervention for patients who might
otherwise do well; however, the acknowledged weak-
nesses of the study may affect our interpretation. In
particular, the short follow-up period of the group who did
not have operation (mean 3.3 y) may affect these results.
Also, the evaluation is limited to those patients who did
not have a functional pancreatic tumor, and provides only
small numbers for comparison among the groups. There
was no consistent standard for imaging, particularly given
the long time frame, which may affect the designation of a
patient as being unaffected by tumors. Finally, as a
non-randomized division between the operated and
non-operated groups, we are left to wonder what the
differences are that may have influenced the decision to
operate. It is likely that differences between institutional
approaches, individual surgeons, or unevaluated patient
characteristics have affected the outcome. In spite of
these limits, it is clear that most patients did very well, and
there was no dramatic improvement in outcome for the
small fraction of patients who did have operation.
Dr. Kouvaraki and colleagues have identified 55 pa-
tients from MD Anderson Cancer Center with pancreatic
endocrine tumors and MEN-1, two-thirds of whom had
functioning tumors.2 Thirty-eight of these patients under-
went pancreatic operations. The rate of recurrent disease
in the residual pancreas postoperatively was 20% at a
median of 7.8 years, and the development of distant dis-
ease in those who presented without metastasis was 14%
at a median of 2.7 years. Most importantly, they demon-
strated an overall and metastasis-free survival improve-
ment in their patients who underwent operation, compared
to those with tumors who did not have operation.
This study also has some limits to its interpretation.
These patients underwent a variety of operations for their
disease, ranging from simple enucleation of tumors to
total pancreatectomy. The criteria for selecting patients
for operation, and the decision about which operation to
perform, were not standardized and may have changed
over time. The follow-up in this study is also short, at a
median of 4.3 years. Finally, the follow-up program is not
presented for us to understand how standardized this is in
determining recurrence rates. The finding of survival
improvement associated with intervention, even in a non-
randomized setting, is noteworthy.
Overall, these two important articles add to the data
that we have to consider in our management of these pa-
tients and present differing views of the same disease
(Fig. 1). The GTE study shows us that many patients with
pancreatic endocrine tumors and MEN-1 do well and so we
must be cautious in our interventions. However, the M.D.
Anderson data indicate that there is some value to inter-
vention in selected patients. For now, the significant out-
standing issue in the management of pancreatic disease in
MEN-1 remains the resolution of these views, including the
proper surveillance regimen for best defining important
disease, the optimal operative timing for prolongation of
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patient survival and quality of life, and the optimal operative
intervention to achieve maximal oncologic benefit while
preserving pancreatic endocrine function.
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Figure 1. Decisions in MEN-1 pancreas intervention.
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